Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.
Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products.
StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use.
National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank.
Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine.
Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
**Proteonomix, Inc. reported that it has formed a new subsidiary called X Gen Medical LLC, a Nevis Virgin Island entity.
X Gen Medical has been established with the intention of conducting business in the global medical marketplace.
Proteonomix plans on utilizing X Gen Medical to serve as a platform for joint ventures with medical facilities worldwide.
It is anticipated that new relationships formed with X Gen Medical will create medical facilities capable of not just attracting treatments locally, but also acting as hubs for medical tourism.
Medical tourism is constantly on the rise and anticipated to continue to grow substantially due to current high costs of health care for certain procedures and improvements in both technology and standards of care in many countries.
Proteonomix, Inc. shares closed friday at $2.35
For more information about this company please visit http://www.proteonomix.com
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.
The Company has successfully commercialized the world's first antisense drug and has 23 drugs in development.
Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.
Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.
Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.
Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.
As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide.
**We have been very successful with our partnerships, bringing in more than $55 million in cash this year, including $35 million from our recent partnership with GSK. Already this year, we have achieved the first milestone under our collaboration with GSK and earned an additional $5 million, one of the factors that has allowed us to improve our guidance. Also contributing to our improved financial performance is revenue we received as a result of Regulus' newly formed alliance with sanofi-aventis and the milestone payments we earned from BMS and Achaogen. Our creation of Regulus with our partners at Alnylam to explore the exciting new area of microRNAs is an example of our continuing commitment and success in expanding our antisense technology platform, said B. Lynne Parshall, COO and CFO of Isis.
Isis Pharmaceuticals, Inc. shares closed friday at $8.38
For more information about this company please visit http://www.isispharm.com
Tiens Biotech Group USA, Inc. (AMEX:TBV) is a leading nutritional products company engaged in the research, development, manufacturing and marketing of high quality nutritional supplements and wellness products worldwide.
Tiens' herbal products, vitamin and mineral supplements and personal care products are sold in China and approximately 90 countries on six continents.
**A rapidly-growing company, Tiens has generated significant revenue and earnings increases by capitalizing on worldwide consumer demand for nutritional and wellness products.
Tiens is well positioned to further expand its market share through product line enhancements and additional channels of distribution.
Tiens Biotech Group USA, Inc. shares closed friday at $1.75
For more information about this company please visit http://www.tiens-bio.com
CRWESelect, a stock highlight publication is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter at http://www.crweselect.com/signup
PLEASE BE SURE TO VISIT CRWESELECT.NING.COM
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)